SCHEMBL692888

SCHEMBL692888

O=C(O)c1ccccc1-c1nc2ccccc2o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
TOP2A P11388 1/20 0.54
RAB9A P51151 8/20 0.53
MAPT P10636 7/20 0.53
NPC1 O15118 7/20 0.53
KDM4E B2RXH2 6/20 0.53
ALDH1A1 P00352 5/20 0.53
HPGD P15428 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HSD17B10 Q99714 4/20 0.53
TP53 P04637 3/20 0.53
PKM P14618 2/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
KDM6B O15054 1/20 0.53
KDM6A O15550 1/20 0.53
USP2 O75604 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29931105 1.00 MEN1 (0.60) MEN1KMT2ATOP2ARAB9AMAPT
SCHEMBL27784903 0.98 MEN1 (0.58) MEN1KMT2ATOP2ARAB9AMAPT
SCHEMBL10749958 0.87 NPC1 (0.51) MEN1KMT2ATOP2ARAB9AMAPT
SCHEMBL11374115 0.87 TOP2A (0.51) MEN1KMT2ATOP2ARAB9AMAPT
SCHEMBL6688214 0.84 MEN1 (0.49) MEN1KMT2ATOP2ARAB9AMAPT
SCHEMBL29931200 0.83 MAPT (0.63) MEN1KMT2ATOP2ARAB9AMAPT
SCHEMBL694337 0.83 MAPT (0.63) MEN1KMT2ATOP2ARAB9AMAPT
SCHEMBL10415956 0.83 HPSE (0.57) MEN1KMT2ATOP2ARAB9AMAPT
SCHEMBL10730860 0.83 HDAC6 (0.56) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL10725269 0.83 MAPT (0.47) MEN1KMT2ARAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108250155-A The novel application containing selenium complexes and its in phenylacetic acid or derivatives thereof synthesis 湖北仙芝堂生物科技有限公司 2018-07-06 CN claimed
US-4659360-A HERBICIDES FMC CORPORATION (US) 1987-04-21 US claimed
US-4265804-A BENZOXAZOYLBENZOATES, OXADIAZOLE-2,5-DIBENZOATES, BENZOTRIAZOLES AND BENZOTRIAZOTRIAZOLES EASTMAN KODAK COMPANY (US) 1981-05-05 US claimed
US-20240208981-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-27 US disclosed
EP-4310089-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-01-24 EP disclosed
EP-4310089-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-01-24 EP disclosed
CN-116981670-A Polycyclic compound containing nitrogen heterocycle, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-10-31 CN disclosed
US-10118919-B2 3-substituted cyclopentylamine derivatives MERCK PATENT GMBH (DE) 2018-11-06 US disclosed
EP-3033339-B1 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2018-02-28 EP disclosed
US-20180022738-A1 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2018-01-25 US disclosed
US-9790216-B2 3-substituted cyclopentylamine derivatives MERCK PATENT GMBH (DE) 2017-10-17 US disclosed
WO-2010124082-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed
WO-2010124112-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed
WO-2010124086-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed
EP-1039915-A4 CYCLIC PHOSPHONATE ESTER INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL MYERS SQUIBB CO (US) 2001-02-14 EP disclosed
EP-1039915-A1 CYCLIC PHOSPHONATE ESTER INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2000-10-04 EP disclosed
US-5962440-A ANTICHOLESTEROL AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 1999-10-05 US disclosed
WO-1999021564-A1 CYCLIC PHOSPHONATE ESTER INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1999-05-06 WO disclosed
US-4659360-A HERBICIDES FMC CORPORATION (US) 1987-04-21 US disclosed
US-4265804-A BENZOXAZOYLBENZOATES, OXADIAZOLE-2,5-DIBENZOATES, BENZOTRIAZOLES AND BENZOTRIAZOTRIAZOLES EASTMAN KODAK COMPANY (US) 1981-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022738-A1 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES FASN, FADS1, ACOX3 MEN1 4353/4885KMT2A 2907/4885TOP2A 657/4885
US-10118919-B2 3-substituted cyclopentylamine derivatives FASN, FADS1, ACOX3 MEN1 4353/4885KMT2A 2907/4885TOP2A 657/4885
US-20240208981-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF HCRTR1, HCRTR2, CCKBR MEN1 251/4885KMT2A 3228/4885TOP2A 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.